These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lentiviral Mediating Genetic Engineered Mesenchymal Stem Cells for Releasing IL-27 as a Gene Therapy Approach for Autoimmune Diseases. Hajizadeh-Sikaroodi S; Hosseini A; Fallah A; Estiri H; Noormohammadi Z; Salehi M; Ghaderian SM; Akhavan Niaki H; Soleimani M; Kazemi B Cell J; 2014; 16(3):255-62. PubMed ID: 24611150 [TBL] [Abstract][Full Text] [Related]
3. Multiple Sclerosis Gene Therapy with Recombinant Viral Vectors: Overexpression of IL-4, Leukemia Inhibitory Factor, and IL-10 in Wharton's Jelly Stem Cells Used in EAE Mice Model. Hosseini A; Estiri H; Akhavan Niaki H; Alizadeh A; Abdolhossein Zadeh B; Ghaderian SMH; Farjadfar A; Fallah A Cell J; 2017 Oct; 19(3):361-374. PubMed ID: 28836399 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143 [TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered Adipose Mesenchymal Stem Cells Using HIV-Based Lentiviral Vectors as Gene Therapy for Autoimmune Diseases. Rostami M; Haidari K; Shahbazi M Cell Reprogram; 2018 Dec; 20(6):337-346. PubMed ID: 30307322 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844 [TBL] [Abstract][Full Text] [Related]
8. The Human IL-23 Decoy Receptor Inhibits T-Cells Producing IL-17 by Genetically Engineered Mesenchymal Stem Cells. Rostami M; Haidari K; Shahbazi M Int J Cell Biol; 2018; 2018():8213912. PubMed ID: 30662466 [TBL] [Abstract][Full Text] [Related]
9. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376 [TBL] [Abstract][Full Text] [Related]
10. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129 [TBL] [Abstract][Full Text] [Related]
11. [Construction of recombinant porcine transforming growth factor beta1 gene lentiviral vector and its expression in bone marrow mesenchymal stem cells]. Lai J; Lin J; Lin W; Wu C Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2012 Jul; 26(7):849-54. PubMed ID: 22905624 [TBL] [Abstract][Full Text] [Related]
12. Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Van Damme A; Thorrez L; Ma L; Vandenburgh H; Eyckmans J; Dell'Accio F; De Bari C; Luyten F; Lillicrap D; Collen D; VandenDriessche T; Chuah MK Stem Cells; 2006 Apr; 24(4):896-907. PubMed ID: 16339997 [TBL] [Abstract][Full Text] [Related]
13. Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis. Godse K Indian J Dermatol; 2017; 62(2):195-199. PubMed ID: 28400641 [TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis. Purmonen T; Törmälehto S; Wahlman H; Puolakka K J Med Econ; 2019 Feb; 22(2):151-157. PubMed ID: 30474450 [TBL] [Abstract][Full Text] [Related]
15. Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses. van Mens LJJ; van de Sande MGH; Menegatti S; Chen S; Blijdorp ICJ; de Jong HM; Fluri IA; Latuhihin TE; van Kuijk AWR; Rogge L; Yeremenko NG; Baeten DLP Arthritis Rheumatol; 2018 Dec; 70(12):1994-2002. PubMed ID: 29869838 [TBL] [Abstract][Full Text] [Related]
16. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. Dokoupilová E; Aelion J; Takeuchi T; Malavolta N; Sfikakis PP; Wang Y; Rohrer S; Richards HB Scand J Rheumatol; 2018 Jul; 47(4):276-281. PubMed ID: 29458278 [TBL] [Abstract][Full Text] [Related]
17. Effect of IL-17 monoclonal antibody Secukinumab combined with IL-35 blockade of Notch signaling pathway on the invasive capability of hepatoma cells. Li HCh; Zhang YX; Liu Y; Wang QSh Genet Mol Res; 2016 Jul; 15(2):. PubMed ID: 27420998 [TBL] [Abstract][Full Text] [Related]
18. A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment. Fallah A; Heidari HR; Bradaran B; Sisakht MM; Zeinali S; Molavi O Life Sci; 2019 Dec; 239():117018. PubMed ID: 31678280 [TBL] [Abstract][Full Text] [Related]
19. Quantitative polymerase chain reaction as a reliable method to determine functional lentiviral titer after ex vivo gene transfer in human mesenchymal stem cells. Böcker W; Rossmann O; Docheva D; Malterer G; Mutschler W; Schieker M J Gene Med; 2007 Jul; 9(7):585-95. PubMed ID: 17510916 [TBL] [Abstract][Full Text] [Related]
20. IL-17A contributes to propagation of inflammation but does not impair adipogenesis and/or insulin response, in adipose tissue of obese individuals. Pestel J; Chehimi M; Bonhomme M; Robert M; Vidal H; Eljaafari A Cytokine; 2020 Feb; 126():154865. PubMed ID: 31629101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]